Plain-English translation of NCT06788431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new injectable medication called IMC-001 to see if it can help stabilize the fatty plaque that builds up inside heart arteries in people with acute coronary syndrome (a sudden heart problem like a heart attack or severe chest pain). About half of the participants will receive the medication along with standard heart medications, and half will receive a placebo injection along with standard care. The study will carefully monitor whether the medication is safe and whether it shows promise in improving plaque stability.
When plaque in heart arteries becomes unstable, it can rupture and cause a heart attack or worsen existing heart disease. Current treatments focus on controlling risk factors, but there are no specific medications designed to make plaque more stable and less likely to rupture. This trial is exploring whether this new treatment could fill that gap.
You likely qualify if…
You likely don't qualify if…
You would visit the study center at least twice—once at the start and once for follow-up—in addition to your regular heart care appointments. At the first visit, you'll undergo imaging tests and blood work to confirm you qualify. Then you'll be randomly assigned to receive either the experimental injection or a placebo injection, both given alongside your standard heart medications. You'll be monitored closely for any side effects and have follow-up imaging and blood tests to see how your plaque is responding.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China